Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Change in Receivables (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Change in Receivables for 11 consecutive years, with -$2.3 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 201.32% to -$2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.6 million through Dec 2025, up 212.67% year-over-year, with the annual reading at $7.6 million for FY2025, 246.68% up from the prior year.
  • Change in Receivables for Q4 2025 was -$2.3 million at Aytu Biopharma, down from $2.1 million in the prior quarter.
  • The five-year high for Change in Receivables was $10.5 million in Q1 2025, with the low at -$6.5 million in Q3 2021.
  • Average Change in Receivables over 5 years is $120894.7, with a median of -$118000.0 recorded in 2023.
  • The sharpest move saw Change in Receivables plummeted 2775.45% in 2022, then surged 2025.42% in 2024.
  • Over 5 years, Change in Receivables stood at $1.3 million in 2021, then plummeted by 277.6% to -$2.4 million in 2022, then soared by 95.04% to -$118000.0 in 2023, then soared by 2025.42% to $2.3 million in 2024, then tumbled by 201.32% to -$2.3 million in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$2.3 million, $2.1 million, and -$4.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.